Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DiaMedica Therapeutics (DMAC) EBITDA (2018 - 2019)

Historic EBITDA for DiaMedica Therapeutics (DMAC) over the last 2 years, with Q4 2019 value amounting to -$2.5 million.

  • DiaMedica Therapeutics' EBITDA fell 2660.55% to -$2.5 million in Q4 2019 from the same period last year, while for Dec 2019 it was -$10.6 million, marking a year-over-year decrease of 8568.19%. This contributed to the annual value of -$24.4 million for FY2024, which is 2655.82% down from last year.
  • DiaMedica Therapeutics' EBITDA amounted to -$2.5 million in Q4 2019, which was down 2660.55% from -$2.5 million recorded in Q3 2019.
  • Over the past 5 years, DiaMedica Therapeutics' EBITDA peaked at -$650000.0 during Q1 2018, and registered a low of -$3.2 million during Q1 2019.